Reduced exposure to calcineurin inhibitors in renal transplantation.
Martijn
M
van den Hoogen
Luuk
L
Hilbrands
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000008:administration & dosage; D000077561:Daclizumab; D016527:Drug Costs; D004359:Drug Therapy, Combination; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000191:economics; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D011241:Prednisone / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065095:Calcineurin Inhibitors; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000077561:Daclizumab; D009173:Mycophenolic Acid; D011241:Prednisone; D016559:Tacrolimus